Clinical Trials Logo

Clinical Trial Details — Status: Completed

Administrative data

NCT number NCT00821548
Other study ID # 07-CIR-01
Secondary ID
Status Completed
Phase N/A
First received January 12, 2009
Last updated January 12, 2009
Start date January 2008
Est. completion date July 2008

Study information

Verified date January 2009
Source Centre Hospitalier Universitaire de Nice
Contact n/a
Is FDA regulated No
Health authority France: Afssaps - Agence française de sécurité sanitaire des produits de santé (Saint-Denis)
Study type Interventional

Clinical Trial Summary

The investigators evaluated clinical tolerance, biological tolerance, feasibility and efficacy of daily electrostimulation training of shoulder girdle and quadriceps muscles in 10 patients with facioscapulohumeral muscular dystrophy, the third most common inherited myopathy.


Description:

Autosomal dominant FSHD is characterized by selective pattern of muscle involvement. Weakness and atrophy typically involve facial and shoulder girdle muscles, and progressively anterior forearm and foreleg muscles and pelvic girdle muscles.

The physiopatholgical mechanism of this disease, due to a deletion of repeated units named D4Z4 located on 4q35, is still controversial. Up to date, no curative therapy is available for these patients. We proposed in the present study to test feasibility, clinical and biological tolerance and efficacy of shoulder muscle training by electrostimulation in a group of FSHD patients. 10 patients displaying classical FSHD phenotype participate to this study consisting in daily session of shoulder girdle and quadriceps muscles electrostimulation of 23 minutes for a period of 5 months.

We evaluated: clinical tolerance by daily pain and fatigue analogic scales, biological tolerance by measuring CK; feasibility: by measuring the monthly score of participation to sessions; the efficacy by manual muscle testing, quantitative muscle assessment, fatigue severity scale.


Recruitment information / eligibility

Status Completed
Enrollment 9
Est. completion date July 2008
Est. primary completion date July 2008
Accepts healthy volunteers No
Gender Both
Age group 18 Years to 75 Years
Eligibility Inclusion Criteria:

- 18 to 75 years old patient

- FSHD diagnosis confirmed by molecular biology

- FSHD clinical phenotype including shoulder girdle and quadriceps involvement

- Patient with Vignos scale = 5 (patient able to walk)

- Patient with health insurance

- Patient that could be followed for at least 6 months

Exclusion Criteria:

- Patient with monolateral or bilateral scapular omopexia

- Patient that has already had electrostimulation training

- Patients with CK values > 5 time normal values

- Patient that has not signed informed consent

- Patient with cancer, collagenopathies or others joint diseases

- Pregnancy and breast-feeding

- Patient on guardianship or trusteeship.

- Patient actively participating to other biomedical researches or whose exclusion period is not ended

- Patient with a formal contraindication to the protocol detected by inclusion examinations

Study Design

Endpoint Classification: Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment


Related Conditions & MeSH terms

  • Facioscapulohumeral Muscular Dystrophy
  • Muscular Dystrophies
  • Muscular Dystrophy, Facioscapulohumeral

Intervention

Procedure:
electrostimulation
Electrostimulation of shoulder girdle and quadriceps muscles in facioscapulohumeral muscular dystrophy patients

Locations

Country Name City State
France CHU de Nice Nice

Sponsors (1)

Lead Sponsor Collaborator
Centre Hospitalier Universitaire de Nice

Country where clinical trial is conducted

France, 

Outcome

Type Measure Description Time frame Safety issue
Primary Clinical tolerance evaluated by fatigue and pain analogic scale. Biological tolerance:evaluated by measuring CK values.The feasibility:evaluated by considering monthly average length of sessions, monthly score of participation to sessions daily, 1, 3 and 5 months No
Secondary Efficacy of electrostimulation training in FSHD patients will be evaluated comparing manual muscle testing, Barré test, quantitative muscle assessment, fatigue severity scale, 6 minutes walking test before the therapy after 3 months of therapy and at the end of the study, after 5 months. No
See also
  Status Clinical Trial Phase
Recruiting NCT00082108 - Myotonic Dystrophy and Facioscapulohumeral Muscular Dystrophy Registry
Completed NCT02579239 - Evaluate Safety and Biological Activity of ATYR1940 in Participants With Limb Girdle Muscular Dystrophy 2B (LGMD2B) and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Terminated NCT02927080 - Study of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 2
Completed NCT02625662 - Facioscapulohumeral Dystrophy in Children
Recruiting NCT04001582 - The United Kingdom Facioscapulohumeral Muscular Dystrophy Patient Registry
Terminated NCT03943290 - Extension Study to Evaluate the Long-Term Effects of ACE-083 in Patients With Facioscapulohumeral Muscular Dystrophy (FSHD) and Charcot-Marie Tooth (CMT) Disease Types 1 and X (CMT1 and CMTX) Phase 2
Completed NCT01596803 - Effects Antioxidants Supplementation on Muscular Function Patients Facioscapulohumeral Dystrophy (FSHD) N/A
Active, not recruiting NCT03458832 - Clinical Trial Readiness to Solve Barriers to Drug Development in FSHD
Completed NCT02766985 - Rasch-analysis of Clinical Severity in FSHD
Active, not recruiting NCT01671865 - Magnetic Resonance Imaging and Spectroscopy Biomarkers for Facioscapulohumeral Muscular Dystrophy
Completed NCT02413190 - Bone Health in Facioscapulohumeral Muscular Dystrophy
Completed NCT01931644 - At-Home Research Study for Patients With Autoimmune, Inflammatory, Genetic, Hematological, Infectious, Neurological, CNS, Oncological, Respiratory, Metabolic Conditions
Completed NCT01437345 - A Multicenter Collaborative Study on the Clinical Features, Expression Profiling, and Quality of Life of Infantile Onset FSHD N/A
Completed NCT02836418 - Study to Evaluate the Long-Term Safety, Tolerability, and Biological Activity of ATYR1940 in Participants With Limb Girdle and Facioscapulohumeral Muscular Dystrophy (FSHD) Phase 1/Phase 2
Not yet recruiting NCT06086548 - Unraveling Metabolic Involvement in Facioscapulohumeral Dystrophy Through Metabolomics
Completed NCT05178706 - Effectiveness of Upper Extremity Rehabilitation in pwFSHD (Patient With Facioscapulohumeral Dystrophia)
Completed NCT00104078 - Study Evaluating MYO-029 in Adult Muscular Dystrophy Phase 1/Phase 2
Recruiting NCT05019625 - Biomarker Development for Muscular Dystrophies
Completed NCT03123913 - Study of Testosterone and rHGH in FSHD Phase 1
Completed NCT04267354 - Arm Cycling in Facioscapulohumeral Dystrophy (FSHD) Patients N/A